Search

• GlaxoSmithKline submits European marketing authorisation application for Pazopanib in advanced kidney cancer

  Media

  GSK announced submission of MAA to EMEA for pazopanib, oral therapy for metastatic renal cell carcinoma (RCC).

  https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-submits-european-marketing-authorisation-application-for-pazopanib-in-advanced-kidney-cancer/

  First published: 04 March 2009

• Regulatory update: Votrient® (pazopanib) as maintenance therapy for advanced ovarian cancer in the EU

  Media

  GSK today announced that it has withdrawn application to EMA for a variation to the Marketing Authorisation for Votrient® (pazopanib).

  https://www.gsk.com/en-gb/media/press-releases/regulatory-update-votrient-pazopanib-as-maintenance-therapy-for-advanced-ovarian-cancer-in-the-eu/

  First published: 31 March 2014

• GSK’s Pazopanib significantly delayed tumor progression in patients with advanced kidney cancer

  Media

  GSK announced results of a Phase III study - pazopanib reduced the risk of tumor progression or death by 54 percent compared to placebo.1

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-pazopanib-significantly-delayed-tumor-progression-in-patients-with-advanced-kidney-cancer/

  First published: 31 May 2009

• GlaxoSmithKline’s pazopanib improved progression free survival in adults with certain soft tissue sarcomas

  Media

  PALETTE study presented at ASCO demonstrated improvement in the time to occurrence of tumour progression in patients on pazopanib vs placebo

  https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-s-pazopanib-improved-progression-free-survival-in-adults-with-certain-soft-tissue-sarcomas/

  First published: 04 June 2011

• European Commission grants marketing authorisation for pazopanib (Votrient®) in the treatment of certain advanced soft tissue sarcoma subtypes

  Media

  GSK announced today the EC has granted pazopanib marketing authorisation for the treatment of aSTS who have received prior chemotherapy.

  https://www.gsk.com/en-gb/media/press-releases/european-commission-grants-marketing-authorisation-for-pazopanib-votrient-in-the-treatment-of-certain-advanced-soft-tissue-sarcoma-subtypes/

  First published: 07 August 2012

• EU and US Regulatory Update - Votrient® (pazopanib)

  Media

  GSK announced it's submitted a Marketing Authorisation Application to EMA for Votrient, the treatment of patients with advanced STR.

  https://www.gsk.com/en-gb/media/press-releases/eu-and-us-regulatory-update-votrientreg-pazopanib/

  First published: 06 July 2011

• GlaxoSmithKline receives conditional marketing authorisation in the EU for Votrient® (pazopanib)

  Media

  As part of these conditions, GSK will provide data from ongoing clinical studies.

  https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-conditional-marketing-authorisation-in-the-eu-for-votrient-pazopanib/

  First published: 14 June 2010

• GSK announces late-stage clinical data for VOTRIENT® (pazopanib) following chemotherapy in women with advanced epithelial ovarian cancer

  Media

  GSK announced its Phase III trial of VOTRIENT met primary objective of a statistically significant improvement in PFS compared to placebo.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-late-stage-clinical-data-for-votrient-pazopanib-following-chemotherapy-in-women-with-advanced-epithelial-ovarian-cancer/

  First published: 01 June 2013

• GSK receives positive opinions in Europe for Tyverb® (lapatinib) and Votrient™ (pazopanib)

  Media

  GSK announced today that CHMP has issued two positive opinions in the European Union for two of its cancer medicines.

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-opinions-in-europe-for-tyverb-lapatinib-and-votrient-pazopanib/

  First published: 18 February 2010

• GSK receives positive opinion from European CHMP for pazopanib in the treatment of patients with certain advanced soft tissue sarcomas

  Media

  GSK announced that the EMA CHMP has issued a positive opinion recommending marketing authorisation for Votrient for the treatment of STS.

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-opinion-from-european-chmp-for-pazopanib-in-the-treatment-of-patients-with-certain-advanced-soft-tissue-sarcomas/

  First published: 25 May 2012